Chemo and immunotherapy plus short targeted drug for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and able to sign informed consent
- Have metastatic or locally advanced non-squamous non-small cell lung cancer (lung adenocarcinoma is expected)
- Have not received prior treatment for metastatic or locally advanced non-small cell lung cancer (some past pre-surgery/prevention chemo is allowed if last injection was >12 months ago)
- PD-L1 on tumor testing is less than 50%, and you can provide recent tumor tissue for testing (existing tissue within 1 month or a new biopsy)
- Have at least one measurable tumor spot on scans and be well enough to do daily activities (ECOG performance 0–1)
- Be willing to get new biopsies: 4 samples at study start and again after Cycle 2 (and for Phase II, 4 samples at start, with a second biopsy 4–5 weeks after starting treatment optional)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests whether monitoring for minimal residual disease (MRD) after surgery can help guide decisions about additional therapy for stage I non-small cell lung cancer (NSCLC). If you've had surgery to completely remove your cancer and are eligible, you may benefit from a personalized approach to follow-up treatment.
This trial tests a combination of two drugs (Adibelimab and Famitinib) plus chemotherapy for people with advanced lung cancer that stopped responding to a PD-1 inhibitor. The goal is to see if this new triple therapy can help shrink tumors or slow down the cancer.
This Phase 1/2 trial tests a combination of an EZH2 inhibitor (tulmimetostat) with a PD-1 blocker (pembrolizumab) for advanced non-small cell lung cancer that has stopped responding to prior PD-1 treatment. It may help shrink or control cancer and is mainly aimed at people who have limited treatment options left.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.